They were able to identify 2 tyrosine kinase inhibitors targetable receptor tyrosine kinases (RTKs) in the tumor cell compartment obtained by laser-capture microdissection, including a previously known epidermal growth factor receptor 1 (EGFR) and a novel ephrin type-A receptor 2 (EPHA2). This evidence concerns the gene EPHA2 and neoplasm.